Background: High-precision three-dimensional (3D) image analysis system has been used for preoperative planning in various fields including thoracic surgery. Such software has made us quite easy to measure lung volume. Change of pulmonary function after surgery has been surveyed in some reports, but there are few reports about lung volume change after surgery. Method: We conducted a retrospective review of 49 patients who underwent lobectomy between January 2014 and June 2016 at General Hospital of Japan Railway Company. We used 3D image analysis system (SYNAPSE VINCENT, Fujifilm Corp, Tokyo, Japan) to calculate lung volume of each patient from computed tomography (CT) images which were taken twice, before surgery and 6 months after surgery. We estimated lung volume change from the difference between those two values. Result: There were 19 right upper lobectomies (RUL), 7 right middle lobectomies (RML), 8 right lower lobectomies (RLL), 5 left upper lobectomies (LUL), and 10 left lower lobectomies (LLL). We performed lobectomies in three different surgical approaches; Thoracotomy (n¼5), Hybrid Video-assisted thoracic surgery (VATS) (n¼24), Complete VATS (n¼20). 7 patients needed pleurodesis after surgery to treat air leakage. The average of total lung volume change was -10.4%. Right lobectomies showed 11.45% decrease of lung volume in average, while left lobectomies showed 5.34% decrease (p¼0.18). Decrease ratio seemed to depend on the way of approaches; Thoracotomy was -19.98% and VATS (hybrid and complete) was -8.58% (p¼0.12). Volume change of patients who underwent pleurodesis after surgery was -20.37%, while the ratio of the others was -7.84% (p¼0.03). Conclusion: VATS seemed to be better in the point of lung volume after lobectomy than thoracotomy. Pleurodesis turned out to reduce lung volume significantly. For furthur study, we will compare lung volume with pulmonary function on a lager aomount of data The effect of insurance types on tumor recurrence and overall survival in resectable non-small cell lung cancer in northern Thailand have never been reported. The aim of this study is to identify the association between Thailand's insurance types and long-term outcomes of treatment. Method: Medical records of patients with non-small cell lung cancer (NSCLC) who underwent pulmonary resection at Chiang Mai University Hospital from January 2002 through December 2016 were retrospectively reviewed. Patients were divided into two groups; patients with National Health Security insurance (NHSI) and patients with Government/State Enterprise insurance or private insurance (GEI). Patient characteristics, pathologic findings and long-term outcomes were assessed. Primary outcome was overall survival; secondary outcome was tumor recurrence. Multivariable cox's regression analysis were used to analyze data. Result: This study included 583 patients; 344 with NHSI and 239 with GEI. Patients with NHSI were more likely to be active smokers, lower % predicted FEV1, present with higher stage tumor, having moderately and poorly differentiated tumor, present with tumor necrosis, and undergo open surgical approach than those with GEI. There were no differences between the two groups in term of lymph node dissection, chemotherapy and postoperative complications. At multivariable analysis, tumor recurrence in patients with GEI was not statistically different from what observed in patients with NHSI (adjusted hazard ratio (HR adj) ¼1.03, 95% CI¼0.51-2.11), however patients with NHSI was more likely to die (HR adj ¼2.45, 95%CI¼1.11-5.42). Conclusion: Thai NSCLC patients with NHSI coverage were more likely to experience shorter overall survival than those with GEI. The difference in medical coverage in each type of insurance, especially in term of regimens of chemotherapy, targeted therapy and immunotherapy may be associated with overall survival of patients. The Thai government should take into account this difference. Keywords: Coverage, treatment outcome, Thai insurance P2.15-29 Eligibility for Anti-Angiogenic Treatments in Patients with Squamous Non-Small Cell Lung Cancer (SQ-NSCLC): EPISQUAMAB Study (GFPC 2015-01) 
